ROQ vs. FAB, CIZ, HEMO, OBD, EVG, MTFB, DEST, GENF, BSFA, and VAL
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include Fusion Antibodies (FAB), Cizzle Biotechnology (CIZ), Hemogenyx Pharmaceuticals (HEMO), Oxford BioDynamics (OBD), Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), Genflow Biosciences (GENF), BSF Enterprise (BSFA), and ValiRx (VAL). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs. Its Competitors
Fusion Antibodies (LON:FAB) and Roquefort Therapeutics (LON:ROQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.
In the previous week, Roquefort Therapeutics had 2 more articles in the media than Fusion Antibodies. MarketBeat recorded 2 mentions for Roquefort Therapeutics and 0 mentions for Fusion Antibodies. Roquefort Therapeutics' average media sentiment score of 1.88 beat Fusion Antibodies' score of 0.00 indicating that Roquefort Therapeutics is being referred to more favorably in the news media.
Roquefort Therapeutics has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fusion Antibodies has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500.
Fusion Antibodies has a net margin of -195.95% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -29.57% beat Fusion Antibodies' return on equity.
21.0% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 1.7% of Roquefort Therapeutics shares are owned by institutional investors. 11.4% of Fusion Antibodies shares are owned by company insiders. Comparatively, 60.4% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Roquefort Therapeutics beats Fusion Antibodies on 9 of the 13 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 7/12/2025 by MarketBeat.com Staff
